Cargando…

Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?

BACKGROUND: Based on current evidence, it is not clear whether lone hypertension increases the risk for severe illness from COVID-19, or if increased risk is mainly associated with age, obesity and diabetes. The objective of the study was to evaluate whether lone hypertension is associated with incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shalaeva, Evgeniya V., Shadmanov, Alisher К., Azizova, Feruza L., Mirakhmedova, Khilola T., Messerli, Franz H., Franco, Oscar H., Saner, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ubiquity Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896243/
https://www.ncbi.nlm.nih.gov/pubmed/35342696
http://dx.doi.org/10.5334/gh.1099
_version_ 1784663119990095872
author Shalaeva, Evgeniya V.
Shadmanov, Alisher К.
Azizova, Feruza L.
Mirakhmedova, Khilola T.
Messerli, Franz H.
Franco, Oscar H.
Saner, Hugo
author_facet Shalaeva, Evgeniya V.
Shadmanov, Alisher К.
Azizova, Feruza L.
Mirakhmedova, Khilola T.
Messerli, Franz H.
Franco, Oscar H.
Saner, Hugo
author_sort Shalaeva, Evgeniya V.
collection PubMed
description BACKGROUND: Based on current evidence, it is not clear whether lone hypertension increases the risk for severe illness from COVID-19, or if increased risk is mainly associated with age, obesity and diabetes. The objective of the study was to evaluate whether lone hypertension is associated with increase mortality or a more severe course of COVID-19, and if treatment and control of hypertension mitigates this risk. METHODS: This is a prospective multi-center observational cohort study with 30-day outcomes of 9,531 consecutive SARS-CoV-2 PCR-positive patients ≥ 18 years old (41.9 ± 9.7 years, 49.2% male), Uzbekistan, June 1-September 30, 2020. Patients were subclassified according to JNC8 criteria into six blood pressure stages. Univariable and multiple logistic regression was conducted to examine how variables predict outcomes. RESULTS: The 30-days all-cause mortality was 1.18% (n = 112) in the whole cohort. After adjusting for age, sex, history of myocardial infarction (MI), type-2 diabetes, and obesity, none of six JNC8 groups showed any significant difference in all-cause mortality. However, age was associated with an increased risk of 30-days all-cause mortality (OR = 1.09, 95%CI [1.07–1.12], p < 0.001), obesity (OR = 7.18, 95% CI [4.18–12.44], p < 0.001), diabetes (OR 4.18, 95% CI [2.58–6.76], p < 0.001), and history of MI (OR = 2.68, 95% CI [1.67–4.31], p < 0.001). In the sensitivity test, being ≥ 65 years old increased mortality 10.56-fold (95% CI [5.89–18.92], p < 0.001). Hospital admission was 12.4% (n = 1,183), ICU admission 1.38% (n = 132). The odds of hospitalization increased having stage-2 untreated hypertension (OR = 4.51, 95%CI [3.21–6.32], p < 0.001), stage-1 untreated hypertension (OR = 1.97, 95%CI [1.52–2.56], p < 0.001), and elevated blood pressure (OR = 1.82, 95% CI [1.42–2.34], p < 0.001). Neither stage-1 nor stage-2 treated hypertension patients were at statistically significant increased risk for hospitalization after adjusting for confounders. Presenting with stage-2 untreated hypertension increased the odds of ICU admission (OR = 3.05, 95 %CI [1.57–5.93], p = 0.001). CONCLUSIONS: Lone hypertension did not increase COVID-19 mortality or in treated patients risk of hospitalization.
format Online
Article
Text
id pubmed-8896243
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ubiquity Press
record_format MEDLINE/PubMed
spelling pubmed-88962432022-03-24 Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes? Shalaeva, Evgeniya V. Shadmanov, Alisher К. Azizova, Feruza L. Mirakhmedova, Khilola T. Messerli, Franz H. Franco, Oscar H. Saner, Hugo Glob Heart Original Research BACKGROUND: Based on current evidence, it is not clear whether lone hypertension increases the risk for severe illness from COVID-19, or if increased risk is mainly associated with age, obesity and diabetes. The objective of the study was to evaluate whether lone hypertension is associated with increase mortality or a more severe course of COVID-19, and if treatment and control of hypertension mitigates this risk. METHODS: This is a prospective multi-center observational cohort study with 30-day outcomes of 9,531 consecutive SARS-CoV-2 PCR-positive patients ≥ 18 years old (41.9 ± 9.7 years, 49.2% male), Uzbekistan, June 1-September 30, 2020. Patients were subclassified according to JNC8 criteria into six blood pressure stages. Univariable and multiple logistic regression was conducted to examine how variables predict outcomes. RESULTS: The 30-days all-cause mortality was 1.18% (n = 112) in the whole cohort. After adjusting for age, sex, history of myocardial infarction (MI), type-2 diabetes, and obesity, none of six JNC8 groups showed any significant difference in all-cause mortality. However, age was associated with an increased risk of 30-days all-cause mortality (OR = 1.09, 95%CI [1.07–1.12], p < 0.001), obesity (OR = 7.18, 95% CI [4.18–12.44], p < 0.001), diabetes (OR 4.18, 95% CI [2.58–6.76], p < 0.001), and history of MI (OR = 2.68, 95% CI [1.67–4.31], p < 0.001). In the sensitivity test, being ≥ 65 years old increased mortality 10.56-fold (95% CI [5.89–18.92], p < 0.001). Hospital admission was 12.4% (n = 1,183), ICU admission 1.38% (n = 132). The odds of hospitalization increased having stage-2 untreated hypertension (OR = 4.51, 95%CI [3.21–6.32], p < 0.001), stage-1 untreated hypertension (OR = 1.97, 95%CI [1.52–2.56], p < 0.001), and elevated blood pressure (OR = 1.82, 95% CI [1.42–2.34], p < 0.001). Neither stage-1 nor stage-2 treated hypertension patients were at statistically significant increased risk for hospitalization after adjusting for confounders. Presenting with stage-2 untreated hypertension increased the odds of ICU admission (OR = 3.05, 95 %CI [1.57–5.93], p = 0.001). CONCLUSIONS: Lone hypertension did not increase COVID-19 mortality or in treated patients risk of hospitalization. Ubiquity Press 2022-03-01 /pmc/articles/PMC8896243/ /pubmed/35342696 http://dx.doi.org/10.5334/gh.1099 Text en Copyright: © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Shalaeva, Evgeniya V.
Shadmanov, Alisher К.
Azizova, Feruza L.
Mirakhmedova, Khilola T.
Messerli, Franz H.
Franco, Oscar H.
Saner, Hugo
Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?
title Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?
title_full Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?
title_fullStr Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?
title_full_unstemmed Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?
title_short Is Lone Hypertension a Risk Factor for More Severe COVID-19 Outcomes?
title_sort is lone hypertension a risk factor for more severe covid-19 outcomes?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896243/
https://www.ncbi.nlm.nih.gov/pubmed/35342696
http://dx.doi.org/10.5334/gh.1099
work_keys_str_mv AT shalaevaevgeniyav islonehypertensionariskfactorformoreseverecovid19outcomes
AT shadmanovalisherk islonehypertensionariskfactorformoreseverecovid19outcomes
AT azizovaferuzal islonehypertensionariskfactorformoreseverecovid19outcomes
AT mirakhmedovakhilolat islonehypertensionariskfactorformoreseverecovid19outcomes
AT messerlifranzh islonehypertensionariskfactorformoreseverecovid19outcomes
AT francooscarh islonehypertensionariskfactorformoreseverecovid19outcomes
AT sanerhugo islonehypertensionariskfactorformoreseverecovid19outcomes